|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6635234||BAYER HLTHCARE||Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning|| |
(10 months ago)
Xofigo is owned by Bayer Hlthcare.
Xofigo contains Radium Ra-223 Dichloride.
Xofigo has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Xofigo are:
Xofigo was authorised for market use on 15 May, 2013.
Xofigo is available in solution;intravenous dosage forms.
Xofigo can be used as therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
The generics of Xofigo are possible to be released after 17 November, 2022.
Market Authorisation Date: 15 May, 2013
Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic